Steroid compound, pharmaceutical composition thereof, and use thereof
By developing a compound with a specific structure to inhibit the SREBP pathway, the treatment challenges of metabolic diseases such as fatty liver have been solved, achieving the effect of reducing liver triglycerides and cholesterol, and providing a new drug for the treatment of fatty liver.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- CHOLESGEN (SHANGHAI) CO LTD
- Filing Date
- 2026-01-26
- Publication Date
- 2026-07-30
AI Technical Summary
Currently, there are no effective drugs for treating fatty liver disease, especially inhibitors targeting the SREBP pathway, which cannot effectively reduce liver triglyceride and cholesterol levels, leading to the occurrence and development of metabolic diseases such as fatty liver.
A novel compound or a pharmaceutically acceptable salt thereof is provided that reduces hepatic triglyceride and cholesterol levels by inhibiting the SREBP pathway, specifically represented by Formula I-0 and Formula I, containing specific carbon atom linkages and substituents that can bind to the SREBP protein and block its activation.
Effectively inhibiting the SREBP pathway, reducing liver triglyceride and cholesterol levels, and preventing and treating metabolic diseases such as fatty liver provide a new treatment strategy.
Smart Images

Figure CN2026074914_30072026_PF_FP_ABST